Renovo Ltd.

There are currently no effective pharmacological treatments to prevent scarring following trauma or surgery. Renovo, a spin-off from the University of Manchester, was set up two years ago with this market in mind. Renovo has two anti-scarring compounds in clinical trials, based on Transforming Growth Factor Beta 3, which appears to promote healing without scarring in embryos, and an antagonist of Transforming Growth Factor Beta 1 and Beta 2, growth factors which appear to be associated with scarring in adults.

Each year, hundreds of millions of people undergo elective surgery or surgery following trauma and are left with scarring. In some cases, such as following appendix removal, the scar may be small enough to go unnoticed. But as the number of traumatic incidents—severe burns, car injuries—rises, so does the incidence of major scarring, which can be both physically and psychologically debilitating. Over 90% of the cases of severe burns occur among a particularly sensitive group—children aged 16 years or less. Although existing wound healing products, such as tissue engineered skin replacements, help restore skin following such extensive injury, there are currently no effective pharmacological treatments to prevent the scarring such procedures can lead to. And rising demand for cosmetic surgery—where an ugly scar could potentially undo the perceived value—suggests that the market for an anti-scarring product extends well beyond accident and burn victims.

Renovo, a spin-off from the University of Manchester, and the first from the Manchester Biotechnology Incubator, was set up two...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip